Integrative multi-omics defines melanoma drug response networks and ARID1A-dependent resistance mechanisms
{{output}}
Resistance to BRAF/MAPK inhibitors is a significant challenge in melanoma treatment, driven by adaptive and acquired mechanisms allowing tumor cells to evade therapy. We explored early signaling responses to BRAF and MAPK inhibition in a BRAFV600E-sensitive me... ...
